このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性固形腫瘍患者におけるBAT8008とBAT1308の併用の安全性、忍容性、薬物動態学的特徴、および予備有効性を評価する臨床研究

2026年9月29日 更新者:Bio-Thera Solutions

進行性固形腫瘍患者におけるBAT8008とBAT1308の併用の安全性、忍容性、薬物動態学的特徴、および予備有効性を評価する多施設共同非盲検第Ib-II相臨床研究

The study, led by Zhejiang Cancer Hospital and sponsored by Bio-Thera Solutions, Ltd., is an exploratory multicenter, open-label phase Ib-II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the combination of BAT8008 with BAT1308 in patients with advanced solid tumors.

This study aims to explore the safety, tolerability, and pharmacokinetic characteristics of BAT8008 combined with BAT1308 in patients with advanced solid tumors, determine the maximum tolerated dose (MTD), provide recommended doses and reasonable dosing regimens for subsequent clinical studies, and preliminarily evaluate the antitumor efficacy.

The study is divided into two stages. The first stage will use a "3+3" dose escalation design to explore the safety and tolerability of the investigational drugs. In the second stage, based on the preliminary safety and efficacy results from the first stage, appropriate doses and tumor types will be selected for expansion studies within the safety dose range to further investigate the safety and clinical efficacy of BAT8008+BAT1308 and provide evidence for subsequent clinical studies.

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (推定)

112

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Zhejiang
      • Hangzhou、Zhejiang、中国、310005
        • Song ZhengBo

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age ≥ 18 years old, gender not specified;

  2. Voluntary signing of the informed consent form;

  3. Must be pathologically diagnosed by histology or cytology, with standard treatment failure or absence of standard treatment, intolerance to standard treatment, or refusal of standard treatment for advanced or metastatic epithelial solid tumor patients. Expanded Research Phase: Divided into two cohorts (the sponsor may expand or delete cohorts of tumor types based on real-time study results): Cohort A: Locally advanced or metastatic triple-negative breast cancer diagnosed by histology or cytology, and subjects who cannot be cured by radical resection or radiotherapy, and have used at least one systemic chemotherapy regimen for advanced or metastatic disease. Cohort B: Other advanced or metastatic epithelial solid tumor patients who are intolerant or refuse standard treatment, prioritizing the following types: non-squamous non-small cell lung cancer, gastric adenocarcinoma, esophageal cancer, small cell lung cancer, cervical cancer, and head and neck squamous cell carcinoma.

  4. According to RECIST 1.1 criteria, there must be evaluable tumor lesions in the dose escalation phase, and at least one measurable tumor lesion in the dose expansion phase;

  5. Eastern Cooperative Oncology Group (ECOG) performance status score required is 0 or 1;

  6. Investigator-assessed expected survival period ≥ 12 weeks;

  7. Must have sufficient organ and bone marrow reserve function, defined as follows:

    Hematology (no blood transfusions, hematopoietic growth factors, or drugs to correct blood cell counts within 14 days prior to first dose):

    Absolute neutrophil count (ANC) ≥ 1.5 × 10^9 /L Platelet count ≥ 90 × 10^9 /L Hemoglobin ≥ 90 g/L

    Coagulation:

    International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5×ULN (for patients not receiving anticoagulation therapy) Patients receiving oral anticoagulant therapy with an INR of 2~3 can be included

    Liver function:

    Total bilirubin (TBIL) ≤ 1.5×ULN For liver cancer or liver metastases, ≤2×ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN For liver cancer or liver metastases, ≤5×ULN

    Renal function:

    Serum creatinine ≤ 1.5×ULN or estimated glomerular filtration rate > 50 ml/min (using Cockcroft-Gault or modified MDRD formula, see appendix) Urine protein: Urinalysis suggests urine protein < 2+ or urine protein quantification < 1g

  8. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and be willing to use effective contraception methods during the study period until 6 months after the last dose; male patients must agree to use effective contraception methods during the study period until 6 months after the last dose; postmenopausal women must have been amenorrheic for at least 12 months to be considered not of childbearing potential;

  9. Willing to provide past archived or fresh tumor tissue samples (if there is no archived tumor tissue in the past, and the investigator assesses that there is a significant risk in obtaining fresh or metastatic tumor tissue specimens, exemption may be granted). Immunohistochemical confirmation of PDL1 and Trop2 expression levels is not required before enrollment, but the sponsor requires the collection of biopsy or archived tumor tissue samples to determine PDL1 and Trop2 expression levels;

  10. Able to understand the requirements of the trial, willing, and able to comply with the trial and follow-up arrangements.

Exclusion Criteria:

  1. Within the first 4 weeks prior to the initial administration of the investigational drug, having received experimental drug therapy or participated in clinical studies of medical devices.
  2. Within the first 4 weeks prior to the initial administration of the drug, having undergone chemotherapy, curative radiotherapy (palliative radiotherapy should be completed within 2 weeks prior to the initial drug administration), biological therapy, endocrine therapy, immunotherapy, or other anti-tumor treatments; 2) For fluoropyrimidine drugs and small molecule targeted drugs, within 2 weeks prior to the initial administration of the investigational drug or within 5 half-lives of the drug (whichever is longer); 3) Within 42 days prior to the initial administration of the investigational drug for nitrosourea drugs or mitomycin C.
  3. Having received, within 1 week prior to drug administration, traditional Chinese medicine or treatment explicitly indicated in the drug instructions approved by the NMPA for its anti-tumor functions, or having a clear record in medical history of herbal treatment for anti-tumor purposes.
  4. Prior anti-tumor therapy resulting in adverse events (AEs) (CTCAE 5.0) still at > Grade 1 before the initial administration of the investigational drug, excluding toxicities judged by the investigator to pose no safety risk, such as alopecia, Grade 2 peripheral neuropathy, etc.
  5. Needing major surgery within the first 4 weeks prior to the initial administration of the investigational drug (excluding procedures for diagnosis) or anticipated major surgery during the study period.
  6. Patients who have previously received Trop2-ADC with small molecule toxins that are topoisomerase I inhibitors.
  7. Having experienced ≥ Grade 3 immune-related adverse events (irAEs) in the past or having discontinued immunotherapy due to irAEs of any grade.
  8. Individuals with a history of allogeneic cell or solid organ transplantation.
  9. Patients with primary central nervous system tumors or symptomatic central nervous system metastases, a history of or currently present meningeal metastases, or a history of seizures. If brain metastases are stable after treatment and there are no new lesions at least 4 weeks before medication, or if asymptomatic lesions are detected for the first time within 4 weeks and the investigator determines disease stability, or if the investigator decides to discontinue corticosteroid treatment 7 days before the initial administration of the investigational drug, then it is allowed.
  10. Any other active malignant tumors within 5 years before the initial administration of the drug, except for locally cured tumors (such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, or ductal carcinoma in situ of the breast).
  11. Occurrence of the following cardiovascular diseases within 6 months before the initial administration of the drug: symptomatic heart failure of New York Heart Association (NYHA) class 2 or higher, left ventricular ejection fraction (LVEF) <50%, unstable arrhythmias or unstable angina, myocardial infarction requiring treatment, pulmonary embolism, uncontrolled hypertension (defined in this protocol as systolic blood pressure >160mmHg and/or diastolic blood pressure >100mmHg despite optimal antihypertensive therapy, and assessed by the investigator to have clinical significance), QTcF >480ms on 12-lead electrocardiogram (QTcF calculated using the Fridericia correction formula).
  12. Presence of any other severe underlying diseases (e.g., Gilbert's syndrome, poorly controlled diabetes, active peptic ulcer, unstable controlled seizures, cerebrovascular events/gastrointestinal bleeding within 3 months before the initial administration of the drug, coagulation disorders with severe symptoms or signs), as judged by the investigator to potentially affect the subject's participation in the study, treatment, and follow-up, affect subject compliance, or potentially lead to occurrences of drug-related complications in the subjects.
  13. History of non-infectious pneumonia/pulmonary inflammation requiring glucocorticoid treatment, current interstitial lung disease (ILD), or subjects in the screening period with suspected ILD/pulmonary inflammation that cannot be ruled out by imaging examinations.
  14. Patients with a history of autoimmune diseases (except for autoimmune thyroid diseases and type I diabetes that can be treated with hormone replacement therapy).
  15. Received systemic corticosteroids (prednisone > 10mg/day or equivalent) or other immunosuppressive agents within 14 days prior to the initial use of the investigational drug; exceptions include the following: use of topical, ocular, intra-articular, intranasal, or inhaled corticosteroids, short-term prophylactic use of corticosteroids (duration not exceeding 2 weeks, e.g., for contrast allergy prophylaxis).
  16. Untreated or actively treated tuberculosis subjects, including but not limited to pulmonary tuberculosis; subjects who have undergone standard anti-tuberculosis treatment and have been confirmed by the investigator to be cured may be included.
  17. Experienced severe infection within 4 weeks prior to the initial administration of the drug or active infection within 2 weeks.
  18. Subjects with the following infectious diseases: Human Immunodeficiency Virus (HIV) infection; active Hepatitis B Virus infection [Hepatitis B Surface Antigen (HBsAg) positive, with Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) > 200 IU/ml or 10^3 copies/ml or within the upper limit of normal value determined by the study center]; Hepatitis C Virus infection [HCV antibody and Hepatitis C Virus Ribonucleic Acid (HCV-RNA) positive]; positive syphilis treponemal antibody and RPR/TRUST positive.
  19. Newly diagnosed thromboembolic events requiring treatment within 6 months (patients with stable lower extremity deep vein thrombosis or port-related thrombosis are allowed to be included).
  20. Difficult-to-control pleural effusion, pericardial effusion, or ascites requiring repeated drainage surgery (monthly or more frequently).
  21. Known hypersensitivity reaction or delayed allergic reaction to any component of the investigational drug.
  22. Known occurrence of ≥ Grade 3 allergic reactions to macromolecular protein preparations/monoclonal antibodies.
  23. History of mental illness, substance abuse, alcoholism, or drug abuse that may affect trial results.
  24. Pregnant or lactating women or individuals planning to conceive.
  25. Other conditions deemed inappropriate for participation in this trial by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:A/ Standard 3+3 2.1mg/kg of BAT8008

Drug: BAT8008, Dosage: 2.1mg/kg, Frequency: once every 2 weeks, Duration: 1year

BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.

実験的:B/ Standard 3+3 2.4mg/kg of BAT8008

Drug: BAT8008, Dosage: 2.4mg/kg, Frequency: once every 2 weeks, Duration: 1year

BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.

実験的:Standard 3+3 200mg of BAT1308

Drug: BAT1308, Dosage: 200mg, Frequency: once every 2 weeks, Duration: 1year

One vial of 4 mL of concentrate contains 100 mg of BAT1308.

実験的:A/ Standard 3+3 1.8mg/kg of BAT8008

Drug: BAT8008, Dosage: 1.8mg/kg, Frequency: Day1 and Day8,once every 3 weeks, Duration: 1year

BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.

実験的:B/ Standard 3+3 2.1mg/kg of BAT8008

Drug: BAT8008, Dosage: 2.1mg/kg, Frequency: Day1 and Day8,once every 3 weeks, Duration: 1year

BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.

実験的:Standard 3+3 300mg of BAT1308

Drug: BAT1308, Dosage: 300mg Frequency: Day1 and Day8,once every 3 weeks, Duration: 1year

One vial of 4 mL of concentrate contains 100 mg of BAT1308.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Dose-limiting toxicity (DLT)
時間枠:The first administration cycle(21 days)

DLT events and their incidence.

The first administration cycle(21 days)
vital signs
時間枠:Through study completion, 1 year

Number of participants with abnormal vital signs

Through study completion, 1 year
Physical examination
時間枠:Through study completion, 1 year

Number of participants with abnormal physical examination

Through study completion, 1 year
Adverse events
時間枠:From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy, whichever occurs earlier,assessed up to 1 year

Number of cases with all adverse medical events that occur after the subject receives the investigational drug assessed by CTCAE V5.0

From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy, whichever occurs earlier,assessed up to 1 year
Clinical laboratory tests
時間枠:Through study completion, 1 year

Number of participants with abnormal clinical laboratory tests

Through study completion, 1 year
Clinical auxiliary tests
時間枠:Through study completion, 1 year

Number of participants with abnormal clinical auxiliary tests

Through study completion, 1 year
Objective response rate (ORR)
時間枠:Through study completion, 1 year

Refer to the proportion of subjects defined as complete remission (CR) and partial remission (PR)

Through study completion, 1 year
Duration of Response(DOR)
時間枠:Through study completion, 1 year

DoR is defined as the time between the first assessment of objective remission of a tumor and death from any cause before the first assessment of Disease progression (PD) , reflecting the duration of ORR.

Through study completion, 1 year
Disease Control Rate (DCR)
時間枠:Through study completion, 1 year

The proportion of patients with tumor reduction or stability maintained for a certain period, including cases of complete response (CR), partial response (PR), and stable disease (SD).

Through study completion, 1 year
Progression Free Survival(PFS)
時間枠:Through study completion, 1 year

Progression Free Survival(PFS )in patients with advanced or recurrent dMMR endometrial cancer treated with BAT1308 combined with platinum-containing chemotherapy were compared with platinum-containing chemotherapy in first-line treatment by IRC according to RECIST V1.1.

Through study completion, 1 year
Overall Survival(OS)
時間枠:Through study completion, 1 year

The time from the date of first administration to the occurrence of death due to any cause. Subjects who were still alive at the time of analysis will use the date of their last contact as the deadline.

Through study completion, 1 year

二次結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetic
時間枠:At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

Level of Tmax

At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).
Pharmacokinetic
時間枠:At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

Level of CL

At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).
Pharmacokinetic
時間枠:At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

Level of T1/2

At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).
Pharmacokinetic
時間枠:At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

Level of Cmax

At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).
Pharmacokinetic
時間枠:At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

Level of ADA

At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).
Pharmacokinetic
時間枠:At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

Level of Nab

At the end of Cycle 1 Day 1 (C1D1), Cycle 2 Day 1 (C2D1), Cycle 3 Day 1 (C3D1), Cycle 3 Day 2 (C3D2), Cycle 3 Day 3 (C3D3), Cycle 3 Day 8 (C3D8), Cycle 4 Day 1 (C4D1), after Cycle4, Every 4 cycle until 26 cycles (one cycle equals 2 weeks).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年4月12日

一次修了 (推定)

2026年11月30日

研究の完了 (推定)

2026年11月30日

試験登録日

最初に提出

2024年3月14日

QC基準を満たした最初の提出物

2024年3月25日

最初の投稿 (実際)

2024年4月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • BAT-8008-1308-001-CR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。